Daily Archives: January 26, 2020

MIAMI, Jan. 22, 2020 /PRNewswire/ -- Pathwaves, a Miami-based digital therapeutics company, has been awarded a U.S. Air Force Small Business Innovation Research (SBIR) Phase I contract through AFWERX and the Air Force Research Lab (AFRL) to advance the development of the NeuroEmpowerment methodology.

Pathwaveshas effectively established a tracked, evidence-based process that quantifies and improves cognitive mental and emotional function. The NeuroEmpowerment process is based on the science of neuroplasticity the brain and body's ability to build new neural pathways and synapses. The methodology is a unique combination of cutting-edge digital integration technology (neurotechnology), coaching and counseling, along with therapeutic mindfulness techniques that provide natural and sustainable results.

During the last decade, approximately 20% of U.S. Air Force personnel have annually been diagnosed with a mental health disorder (source January 2017 Deployment Health Clinical Center report). Pathwaves has been highly successful in relieving symptoms of PTSD, anxiety, depression, sleep issues, ADD/ADHD and an array of other issues.

"Our team is excited about the opportunity to work with the dedicated men and women who serve in the U.S. Air Force. We look forward to helping them to function at their optimum with our NeuroEmpowerment process," says Geoff Cole, Founder and CEO of Pathwaves.

The Pathwaves NeuroEmpowerment platform will, for the first time, provide the U.S. Air Force with the ability to objectively quantify their personnel's level of mental function. The process begins with the proprietary NeuroQuant as the first step of their modern approach to not only resolving mental health issues, but enabling the highest levels of mental performance. The NeuroQuant reveals the areas of imbalance, and is followed by an average of 12 neurofeedforward sessions a proprietary process that uses neurtechnology to create new, previously non-existent neural pathways and synaptic connections. The sessions are designed to correct the imbalances and are supported by therapy and coaching. The methodology is non-invasive and medication-free.

For more information, visit pathwaveslife.com, email getbalanced@pathwaves.comor call (305) 858-6616.

Pathwavesis a Miami-based digital therapeutics company specializing in NeuroEmpowerment - a proprietary, multi-dimensional and transformative methodology that uses the powerful principles of neuroplasticity, neurotechnology, therapy and coaching to help individuals attain their optimal state of mental, emotional, spiritual and physical harmony.

About AFWERX: Established in 2017 by the Secretary of the Air Force, AFWERX is a catalyst for agile Air Force engagement across industry, academia, and non-traditional contributors to create transformative opportunities. The core mission of AFWERX is to improve Air Force capabilities by connecting innovators, simplifying technology transfer and accelerating results. AFWERX has partnered with the AFRL, a scientific research organization operated by the U.S. Air Force Materiel Command, to streamline the SBIR process to speed up the experience, broaden the pool of potential applicants, and decrease bureaucratic overhead.

Media Contact:Ana Margarita305.431.0300232811@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/united-states-air-force-plans-to-aim-high-leveraging-the-science-of-neuroplasticity-300991024.html

SOURCE Pathwaves

Read the original post:

United States Air Force Plans to "Aim High" Leveraging the Science of Neuroplasticity - Yahoo Finance

NEW YORK, Jan. 22, 2020 /PRNewswire/ --

The global facial recognition market size to grow at a Compound Annual Growth Rate (CAGR) of 16.6% during the forecast period

Read the full report: https://www.reportlinker.com/p05208353/?utm_source=PRN

MarketsandMarkets forecasts the global facial recognition market size to grow from USD 3.2 billion in 2019 to USD 7.0 billion by 2024, at a CAGR of 16.6% during 20192024. The rising need for surveillance has become one of the major factors to drive the facial recognition market. The advent of new technologies, such as high-definition Closed Circuit Television (CCTV) and high-resolution 3D facial recognition technologies, along with iris recognition and emotion detection, has enhanced the facial recognition market. However, integration of new facial recognition technologies with the existing legacy system is limiting the growth of facial recognition solutions in the market.

Government and defense sector among verticals to gain maximum traction during the forecast periodIncreasing need of facial recognition-enabled biometrics solutions for identity management, border management, and homeland and military security management have fueled government organizations to largely implement facial recognition technologies. Additionally, government-owned large-scale programs, such as smart cities and smart transportation, need the adoption of facial recognition solutions.3D facial recognition software tools to hold the largest market size during the forecast period3D facial recognition software is capable of analyzing, identifying, and verifying facial characteristics of individuals. It overcomes the drawbacks of 2D facial recognition and can work in low light or completely dark areas. 3D facial recognition technology is used mostly in cross- border monitoring, document verification, and identity management.

Asia Pacific to grow at the highest CAGR during the forecast periodThe Asia Pacific (APAC) region has a great scope for growth in the facial recognition market in terms of usage of the facial recognition solution.The facial recognition market in APAC is anticipated to grow significantly, due to huge governmental investments in security and surveillance infrastructure, increased public awareness, and emergence of refined technologies backed by analytics.

Futhermore, growth is anticipated with technological advancements, along with the mandatory regulations imposed by government regulatory entities to adopt the best-in-class technologies and standards. Fast expansion of regional enterprises in the APAC region is another crucial variant contributing to the growth of the facial recognition market.In the process of determining and verifying the market size for several segments and subsegments gathered through secondary research, extensive primary interviews were conducted with key people.

The breakup profiles of the primary participants are as follows: By Company: Tier I: 15%, Tier II: 42%, and Tier III: 43% By Designation: C-Level: 62%, Director Level: 20%, and Others: 18% By Region: North America: 40%, APAC: 30%, Europe: 20%, MEA: 5%, and Latin America: 5%

The report includes the study of the key players offering facial recognition solutions. It profiles major vendors in the global facial recognition market including NEC (Japan), Aware (US), Gemalto (Netherlands), Ayonix Face Technologies (Japan), Cognitec Systems GmbH (Germany), NVISO SA (Switzerland), Daon (US), StereoVision Imaging (US), Techno Brain (Kenya), Neurotechnology (Lithuania), Innovatrics (Slovakia), id3 Technologies (France), IDEMIA (France), Animetrics (US), and MEGVII (China).

Research coverageThe report segments the global facial recognition market by component, application area, vertical, and region.The application area segment comprises emotion recognition, attendance tracking and monitoring, access control, law enforcement, and others (robotics and eLearning).

The verticals segment comprises 7 verticals, namely, Banking, Financial Services, and Insurance (BFSI); government and defense; retail and eCommerce; healthcare; education; automotive; and others (manufacturing, telecom, and energy and utilities).The facial recognition market by offering has software tools and services.

The report covers the facial recognition market with respect to 5 major regions: North America, Europe, APAC, Latin America, and Middle East and Africa (MEA).

The report would help the market leaders and new entrants in the global facial recognition market in the following ways:1. The report segments the market into various subsegments, hence it covers the market comprehensively. It provides the closest approximations of the revenue numbers for the overall market and its subsegments. The market numbers are further split across applications and regions.2. It helps in understanding the overall growth of the market. It also provides information about key market drivers, restraints, challenges, and opportunities.3. It helps stakeholders in understanding their competitors better and gaining more insights to strengthen their positions in the market. The study also presents the positioning of the key players based on their product offerings and business strategies.

Read the full report: https://www.reportlinker.com/p05208353/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/marketsandmarkets-forecasts-the-global-facial-recognition-market-size-to-grow-from-usd-3-2-billion-in-2019-to-usd-7-0-billion-by-2024--at-a-cagr-of-16-6-during-20192024--300991066.html

SOURCE Reportlinker

Read the original:

MarketsandMarkets forecasts the global facial recognition market size to grow from USD 3.2 billion in 2019 to USD 7.0 billion by 2024, at a CAGR of...

Have you ever considered the possibility that wearable technology could vastly improve your life? The innovators at the WearTech Applied Research Center have. In fact, these entrepreneurs arent simply considering the health and lifestyle benefits of WearTech, theyre creating it.

The WearTech Applied Research Center, a collaboration between Arizona State University and local government, economic and healthcare organizations, opened in October in the newly-renovated Park Central and is positioning the Phoenix metro area to be the hub of wearable technology innovation. The first-of-its-kind applied research center will support an entrepreneurial ecosystem to improve quality of life and human performance through the development of innovative wearable technologies.

Our goal with this institute is that we become proud Arizonans of an Arizona-based intellectual property generation, said Chris Camacho, president and CEO of the Greater Phoenix Economic Council (GPEC). Its less about importing other states and other peoples technology and more about building our own.

With the help of a $750,000 grant that was awarded to GPEC from the U.S. Department of Commerce, Arizonas MedTech innovators are changing the way consumers, medical providers, and the world view health and technology. And, in doing so, they are expected to further brand Arizona as the most innovative and forward-thinking MedTech center in the nation.

The WearTech grant originates from the Economic Development Administrations 2018 Regional Innovation Strategies program competition and it aimed at accelerating wearable and medical technology entrepreneurship in Greater Phoenix. The distribution of funds will be facilitated by GPEC, the Center for Entrepreneurial Innovation (CEI) at the Maricopa County Community College District, Arizona State University (ASU), the Partnership for Economic Innovation (PEI), and StartupAZ Foundation.

We were very fortunate that a year ago as we went out and talked to the Legislature about garnering support the Wearable Technology Center, Camacho says. The Legislature afforded us with the governors support dollars to go build what we built at Park Central. Immediately upon finalizing the legislation, we were oversubscribed for the number of private sector WearTech companies that were seeking out the grant infrastructure that the state provided.

When discussing WearTech, those not well-versed with MedTech and wearable technology may wonder, What are we really talking about?

Wearable technology is identified as first being able to be physically wearable on the body, says Joe Hitt, co-founder and CEO of GoX Labs, which operates out of the WearTech Applied Research Center. Second, it needs to be able to do something a quantitative measure monitor heart rate, sleep or even glucose levels.

The SmartWatch is probably the most recognizable type of wearable technology, but earbuds, head-wraps, harnesses and exoskeletons are additional examples.

Wearable medical technology is the next generation of healthcare and can improve the quality of life for patients, said Christine Mackay, director of Phoenix Community and Economic Development.

Among the residents and early innovators that are calling the 5,000-square-foot WearTech Center at Park Central mall in Midtown Phoenix home are:

Hoolest Performance Technologies. The company is focusing on an electrical nerve stimulator earbud that calms anxiety.

GoX Labs. Researchers are developing human exoskeleton standards and testing research in the pursuit of improved mobility and performance.

Flexbio and TrueMobile Health. The company is working on an absorbent patch that can detect the presence of alcohol in sweat and is paired with software for wearable technology.

LevelUp. This company is producing a baseball hat with an EEG headband that utilizes neurofeedback to enhance human performance.

The diverse projects housed in the WearTech Applied Research Center could not be more perfectly positioned, with the Phoenix Biomedical Campus, Barrow Neurological Center and a host of other predominant healthcare providers in close proximity.

WearTech Center in Phoenix will focus on development and research in areas including wearable technologies, wearable robotics, bioelectronics medicine and neurotechnology development with the goal to improve quality of life and human performance. (Photo by Alyssa Tufts, AZ Big Media)

While the physical logistics for the WearTech Center are optimal for its resident innovators, so is the logistic positioning within the growing MedTech sector. Arizona is becoming an increasingly more competitive arena for companies like Hoolest Performance Technologies,GoX Labs, Flexbio and TrueMobile Health and LevelUp.

Why now? Why should entrepreneurs and thought leaders in the MedTech space turn their attention to the Valley?

Because now, the need for wearable technology, combined with public awareness knowledge, is intercepting, Hitt says. Prior, the public wasnt aware of this type of medical technology.And the need for this technology has become more apparent with the rise of preventative diseases 80 percent of chronic diseases are preventable.

Furthermore, according to Hitt, insurers, consumers, medical providers and employers are starting to realize the potential to predict and monitor the progression of medical conditions.

Wearables will help us predict chronic diseases and help us change behavior on a massive scale, he says.

While greater awareness of wearable technology and what it can do in the healthcare industry certainly underscores the idea of right timing, so does having the support and access to research and a pipeline of talent from local universities.

If you look at the top innovation hubs globally, the centerpiece is always a strong research university or universities, says Kyle Squires, dean for the Ira A. Fulton Schools of Engineering at ASU. This collaborative center converges our world-class faculty and impactful research with industry partners ideas and needs. It embeds our ability to effectively translate fundamental research into the marketplace at the pace of industry and make ASUs backyard the competitive home of wearable medical technology.

Camacho says ASU is continuing to fuel the labor force needed for these innovative startups by pursuing an aggressive plan to keep building one of the best engineering schools in the nation.

This new federal award provides a great opportunity to strategically expand the scope, scale and reach of our MedTech Ventures Program adds Gregory Raupp, director of the MacroTechnology Works Initiative and foundation professor of engineering at ASU. As the award encourages expansion in MedTech, it also promotes opportunity for continued intellectual property to be created in Arizona.

That is something Camacho stresses as vital to shaping Greater Phoenix as the hotbed for WearTech development and advancement.

I expect in the next few years, we will have a myriad of innovation centers across this central hub the location of the WearTech Applied Research Center in Central Phoenix that will redefine our city as we know it, Camacho says.

Now that legislators have what Camacho refers to as a taste of what these innovations are, he expects more of a very good thing to come from Arizonas groundbreaking MedTech innovators.

As we put more and more of these in play, were going to be wildly successful in not only recruiting companies, but growing the base of companies in Arizona, he says.

Industry analyst firm CCS Insight estimates the wearable technology industry, with more than 245 million devices sold in 2019 alone, is worth $25 billion globally.

Today, there are more than 133,600 innovators and businesses in the Valleys wearable technology workforce, Mackay adds. This includes electronic, biomechanical and mechanical engineers, electrical and electronic technicians and software developers, plus supporting occupations and vendors. This is a field that can draw upon experience, knowledge and acumen horizontally across many industries.

And, Mackay says, The Valley is establishing prominence at the inception of the industry. Its a pioneering effort,and Phoenix is the world center of the pioneer spirit.

Read this article:

Wearable technology drives Phoenix to be leader in innovation - AZ Big Media

Eli Lilly and Company (LLY) is looking forward to growing its portfolio through acquisitions and mergers. Company CFO John Smiley reported that the pharma giant is planning to clock $1 billion to $5 billion worth of deals for each quarter of 2020.

The announcement comes on the heels of its latest acquisition worth $1.1 billion. Under this deal, the company would be acquiring dermatology products maker Dermira. The companies plan to close the deal by the end of the quarter. Dermira currently has only one product in the market which is Qbrexza (glycopyrronium) cloth for treating excessive sweating in underarms or primary axillary hyperhidrosis. The treatment had closed $10.2 million in revenue during the last quarter. Dermira also has one lead drug candidate in Phase 3 stage which is aimed at treating atopic dermatitis.

Eli Lilly plans to focus on early stage pharma companies dealing in areas such as pain, immunology, neurology and oncology. While the company had been on an acquisition spree for quite some time, this year it is planning to take its growth strategy to a new level. The main reasons behind these acquisitions are to populate its product pipeline and grow its revenues. With more and more of its older products facing competition from generics, Eli Lilly is looking at other options to boost its position in the market.

In the past couple of years, the company has made considerable investment in the cancer segment including the $8 billion acquisition deal for Loxo Oncology. The deal led to the inclusion of Vitrakvi to Eli Lillys portfolio. The drug is designed to treat a wide range of cancers caused by a rare genetic mutation. While the market expected the company to continue with its oncology theme for acquisitions, the latest announcement shows that Eli Lilly is looking to widen its horizons and enter new markets.

Eli Lilly possesses adequate resources to fund its buying spree. During its most recent earnings announcement, the company provided better than expected guidance for 2020. It projected 2020 revenue to be in the range of $23.6 billion and $24.1 billion, surpassing consensus estimate of $23.5 billion. The company also expects its adjusted earnings to be in between $6.70 and $6.80 per share range.

Eli Lilly is mainly banking upon higher demand for its new products such as Taltz and Trulicity. The former is developed for treating psoriasis and other related autoimmune diseases while the latter is for treating diabetes. The company expects that these new drugs will be able to make up for the losses caused due to increased generic competition for other established products of Eli Lilly. In 2019, the companys flagship product Cialis lost its exclusivity, putting a dent in the companys top line.

Eli Lilly stock posted close to 20 percent gain in the past 12 months and the company is looking forward to a strong year ahead. With its strong drug pipeline, which Eli Lilly plans to grow both organically as well as through acquisitions, the company is in a position to retain its leadership stance in the market. In the coming year, Eli Lilly is going to have several important milestones coming up including the FDA decision for two new drug candidates including a diabetes treatment. Further, the company is also looking forward to market launches. Overall, the scenario looks rosy for the company.

Helius Medical Technologies (HSDT) reported that it has entered into collaboration with the University Health Network in Canada. The agreement deals with conducting a clinical experience program which will enable the Network and three independent neurorehabilitation clinics to appraise the Companys Portable Neuromodulation Stimulator (PoNS) device along with the physical therapy, on people suffering from chronic balance deficit caused by mild-to-moderate traumatic brain injury.

The collaboration will help the Network assess the device and decide the extent to which these may be incorporated into their clinical practices. The Portable Neuromodulation Stimulator (PoNS) is an authorized class II, non-implantable, medical device in Canada intended for use as a short-term treatment aimed at patients with chronic balance deficit. The device is currently under review for clearance by the AUS Therapeutic Goods Administration.

Helius stock has been thrashed over the course of the past one year. The new collaboration is expected to provide a positive fillip to the stock. The company mainly deals with developing neurotechnology products which are non-invasive in nature. With this new collaboration, the company may look forward to more robust top line growth with access to new markets.

Durect Corporation (DRRX) stock stumbled as the company provided an update about its Posimir treatment. The FDA advisory committee deliberating about the fate of this treatment ended its meeting with a split vote. Posimir is being developed as an extended release solution for treating post-surgical pain. While the treatment received positive response from six of the committee members, the other six members voted against it. The company CEO James Brown said that the company intends to keep working with the FDA for the review purpose.

Durect management remains optimistic about the outcome as the FDA is not obliged to follow the recommendation of the committee. The Anesthetic and Analgesic Drug Products Advisory Committee was convened to review the Class 2 New Drug Application (NDA) resubmission for the treatment. The company had received a CRL for the treatment in 2014. Posimir has been through 16 clinical trials so far. These trials involved over 1,400 subjects. Out of these patients, 850 were administered Posimir while others were kept in control groups.

Durects clinical development program is designed to assess the safety and efficacy of a single dose of POSIMIR for treating post-surgical pains for up to three days. In its two completed trials, the drug showed significant reduction in pain over the time period of 0 to 72 hours after the surgery.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

See original here:

Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha